Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 24Genitourinary 3Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 14Neoplasms 5Adenocarcinoma of Lung 4Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Mesothelioma 2Colorectal Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Sorafenib × Thoracic × Clear all
NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡